Overview

Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether this topical NF-kappaB Decoy candidate is safe in persons with atopic dermatitis. Preliminary evidence of efficacy (whether it is working) will also be evaluated.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Anesiva, Inc.
Treatments:
Carisoprodol